CharlesHenryNashIIIMD

Clinical Trials

• S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Start of enrollment: 2007 Jul 01

  Completed

  Phase 2

• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01

  Active, not recruiting

  Phase 3

• S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Start of enrollment: 2008 Dec 01

  Completed

  Phase 2

• S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Start of enrollment: 2010 Apr 01

  Completed

  Phase 2

• S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01

  Completed

• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15

  Active, not recruiting

  Phase 3

• S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Mar 01

  Recruiting

  Phase 3

• S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Start of enrollment: 2012 Feb 01

  Completed

  Phase 3

• NBRST: Prospective Neo-adjuvant REGISTRY Trial Start of enrollment: 2011 Jul 01

  Completed

• PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01

  Completed

• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Apr 01

  Active, not recruiting

  Phase 3

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01

  Active, not recruiting

  Phase 3

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Join now to see all